People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Healthtech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grail, Inc. | — | Biotechnology | Growth/Late | $2.2B | $2.9B | 2019 |
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Cue Health Inc. | — | Healthtech | Series D+ | $125.7M | $2.6B | 2020 |
| Mirvie, Inc. | — | Other | Series B | $23.7M | $113.3M | 2025 |
| GenturaDx, Inc. | — | Biotechnology | Series A | $4.0M | $144.8M | 2011 |
MIN CUI at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MIN CUI on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Samir Kaul | 1 | 32 |
| Robert Nelsen | 1 | 22 |
| Scott L. Glenn | 1 | 9 |
| Shervin Pishevar | 1 | 8 |
| Richard Klausner | 1 | 7 |
| Rohan Oza | 1 | 7 |
| Alan Colowick | 1 | 7 |
| Cam Gallagher | 1 | 7 |
| Stanley Lapidus | 1 | 7 |
| Scott Stanford | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| Mark Chin | 1 | 4 |
| William Rastetter | 1 | 4 |
| Naomi Kelman | 1 | 3 |
| Hans Bishop | 1 | 3 |
| Jayson Punwani | 1 | 3 |
| Mark Bagnall | 1 | 3 |
| Catherine Friedman | 1 | 3 |
| William T. Rastetter | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.